Pharma BD Deal Intelligence

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. / AriBio Co., Ltd.

2026 · Licensing/Option · $240M · Complete

Shanghai Fosun Pharmaceutical and AriBio signed an exclusive global option agreement covering development, registration, manufacturing and commercialization of AR1001 (mirodenafil), an oral once-daily PDE5 inhibitor in the global Phase 3 POLARIS-AD trial for early Alzheimer's disease. The structure is an option fee plus license payment: Fosun pays AriBio a USD 60 million option fee and may decide, within 90 days of receiving topline Phase 3 data, whether to exercise. On exercise Fosun would pay up to a further USD 180 million in upfront and regulatory milestone payments, taking the disclosed total to up to USD 240 million. Rights on exercise cover global markets excluding China, Hong Kong, Macau, ten Southeast Asian countries and certain other territories.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals